Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post‐marketing data

维多利祖马布 医学 恶性肿瘤 溃疡性结肠炎 内科学 入射(几何) 医学名词 炎症性肠病 人口 胃肠病学 肿瘤科 疾病 不利影响 药物警戒 光学 物理 环境卫生
作者
Tim Card,Ryan C. Ungaro,Fatima Bhayat,Aimee Blake,Gary Hantsbarger,Simon Travis
出处
期刊:Alimentary Pharmacology & Therapeutics [Wiley]
卷期号:51 (1): 149-157 被引量:46
标识
DOI:10.1111/apt.15538
摘要

BACKGROUND: integrin approved to treat moderate-to-severe Crohn's disease and ulcerative colitis in adults. Inflammatory bowel disease (IBD) and immunosuppressant use are associated with increased risk of malignancy. AIM: To analyse the incidence of malignancy with vedolizumab treatment in the GEMINI long-term safety (LTS) study and post-marketing (PM) setting. METHODS: Malignancy data from the LTS study (May 2009 to May 2018), and data from the vedolizumab Global Safety Database (20 May 2014 to 19 May 2018), were identified using Medical Dictionary for Regulatory Activities coding. The number of patients experiencing malignancies in the LTS study (excluding malignancies within 1 year following vedolizumab initiation) was indirectly standardised against the number expected, using age- and sex-specific rates in patients with IBD from Optum's Clinformatics™ Data Mart (CDM) database. RESULTS: Among 1785 patients with ≥1 year of follow-up post-vedolizumab initiation in the LTS study (total 5670 patient-years), observed numbers of malignancies were similar to those expected compared with CDM data (31 vs 29; ratio of observed to expected events = 1.08; P = 0.71; 95% confidence intervals [CI] 0.73, 1.53). The most common malignancies were renal and bladder (6). PM, 293 patients reported 299 malignancies (including malignancies within 1 year following vedolizumab initiation), in approximately 208 050 patient-years of vedolizumab exposure. Lower gastrointestinal malignancies were most common (59). CONCLUSIONS: The number of malignancies in the LTS study was similar to that expected from an IBD population with no statistically significant differences, although few confounders could be corrected for. Limitations of PM safety reporting require consideration; however, the number of malignancies with vedolizumab appeared low.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Czz发布了新的文献求助10
刚刚
1秒前
serena发布了新的文献求助20
1秒前
忧心的曼凝的应助被沧海云帆采纳,获得10
1秒前
QQ完成签到,获得积分10
1秒前
1秒前
Brian发布了新的文献求助10
1秒前
nn完成签到,获得积分10
2秒前
科研通AI6.4的应助被Wd采纳,获得10
2秒前
石心粥发布了新的文献求助10
2秒前
3秒前
爆米花的应助被MRCHONG采纳,获得10
3秒前
小马同学发布了新的文献求助10
3秒前
搜集达人的应助被坚定的问芙采纳,获得10
4秒前
年轻雁枫完成签到,获得积分10
4秒前
sun发布了新的文献求助10
4秒前
俊逸博超完成签到,获得积分10
4秒前
hhhhh完成签到,获得积分10
4秒前
周周周发布了新的文献求助10
4秒前
哭泣冬瓜完成签到,获得积分10
5秒前
星辰大海的应助被繁荣的尔风采纳,获得10
5秒前
IceyCNZ完成签到,获得积分10
7秒前
7秒前
科研通AI2S的应助被春天采纳,获得10
8秒前
fancccc完成签到,获得积分10
8秒前
8秒前
1101592875发布了新的文献求助10
9秒前
李健的小迷弟的应助被米饭采纳,获得10
9秒前
10秒前
小马同学完成签到,获得积分10
10秒前
fancccc发布了新的文献求助10
11秒前
小马甲的应助被lsx采纳,获得10
11秒前
NexusExplorer的应助被屹男采纳,获得10
12秒前
李健的小迷弟的应助被vbmc采纳,获得30
12秒前
13秒前
13秒前
李健的小迷弟的应助被青衫采纳,获得10
14秒前
14秒前
丽丽的账号完成签到,获得积分10
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183792
求助须知:如何正确求助?哪些是违规求助? 9573020
关于积分的说明 21828776
捐赠科研通 7780959
什么是DOI,文献DOI怎么找? 3434116
关于科研通互助平台的介绍 2558301
邀请新用户注册赠送积分活动 2480611